All Ventyx Biosciences articles
-
NewsLilly acquires inflammatory firm Ventyx Biosciences for $1.2bn deal
The deal brings it access to oral therapies targeting inflammatory-mediated conditions, including cardiometabolic, neurodegenerative and autoimmune diseases.